Live feed
·
INSIDERFilingvia Quantisnow
Stoke Therapeutics Inc. logo

Director Kaye Edward M. Md converted options into 61,750 shares, increasing direct ownership by 126% to 110,874 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
STOK· Stoke Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track STOK (Stoke Therapeutics Inc.) and more on Quantisnow.